New drug combo shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT02940301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining ibrutinib and nivolumab can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatment. About 18 adults will receive both drugs to see if the cancer shrinks or disappears. The goal is to improve disease control, not to cure the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Winship Cancer Center of Emory University
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial